TNF and hemophagocytic syndrome: Ruxolitinib, as a JAK 1 and 2 inhibitor, has been tested in mouse models of hemophagocytic lymphohistiocytosis (HLH) and found to promote survival and reduce levels of proinflammatory cytokines IL-6 and TNF-α (4, 5).